A RETROSPECTIVE ANALYSIS OF PATIENTS WITH RECURRENT HIGH-GRADE GLIOMAS TREATED WITH BEVACIZUMAB WITH OR WITHOUT IRINOTECAN: THE MOFFITT CANCER CENTER EXPERIENCE

被引：0
|
作者：
Potthast, Lisa [1 ]
Chowdhary, Sajeel [1 ]
Pan, Edward [1 ]
Yu, Daohai [1 ]
Brem, Steven [1 ]
机构：
[1] Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA
来源：
NEURO-ONCOLOGY | 2008年 / 10卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：831 / 831
页数：1
相关论文
共 50 条
  • [1] Efficacy, toxicity, and pattern of response and progression in patients with high-grade gliomas treated with bevacizumab and irinotecan: Experience in one center.
    Gallardo Martin, E.
    Areses Manrique, M. C.
    Anido Herranz, U.
    Aguin Losada, S.
    Brozos Vazquez, E.
    Vieito Villar, M.
    Castro Gomez, J. E.
    Leon, L.
    Lamas, M. J.
    Lopez, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [2] FDG-PET predicts survival in recurrent high-grade gliomas treated with bevacizumab and irinotecan
    Colavolpe, Cecile
    Chinot, Olivier
    Metellus, Philippe
    Mancini, Julien
    Barrie, Maryline
    Bequet-Boucard, Celine
    Tabouret, Emeline
    Mundler, Olivier
    Figarella-Branger, Dominique
    Guedj, Eric
    NEURO-ONCOLOGY, 2012, 14 (05) : 649 - 657
  • [3] Circulating endothelial cells and progenitors in recurrent high-grade gliomas treated with bevacizumab and irinotecan.
    Eoli, M.
    Calleri, A.
    Cuppini, L.
    Anghileri, E.
    Pellegatta, S.
    Prodi, E.
    Bruzzone, M. G.
    Bertolini, F.
    Finocchiaro, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [4] Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan
    R. M. Zuniga
    R. Torcuator
    R. Jain
    J. Anderson
    T. Doyle
    S. Ellika
    L. Schultz
    T. Mikkelsen
    Journal of Neuro-Oncology, 2009, 91 : 329 - 336
  • [5] Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan
    Zuniga, R. M.
    Torcuator, R.
    Jain, R.
    Anderson, J.
    Doyle, T.
    Ellika, S.
    Schultz, L.
    Mikkelsen, T.
    JOURNAL OF NEURO-ONCOLOGY, 2009, 91 (03) : 329 - 336
  • [6] Bevacizumab in Recurrent High-Grade Gliomas: A Canadian Retrospective Study
    Fat, Mary Jane Lim
    Maurice, Catherine
    Maganti, Manjula
    Mason, Warren P.
    CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES, 2018, 45 (01) : 56 - 61
  • [7] BEVACIZUMAB FOR RECURRENT HIGH-GRADE GLIOMAS
    Sahebjam, Solmaz
    Garoufalis, Evgenia
    Guiot, Marie Christine
    Muanza, Thierry
    Del Maestro, Ronaldo
    Kavan, Petr
    NEURO-ONCOLOGY, 2010, 12 : 43 - 43
  • [8] RE-IRRADIATION WITH AND WITHOUT BEVACIZUMAB IN RECURRENT OR PROGRESSIVE HIGH-GRADE GLIOMAS (HGG): RETROSPECTIVE ANALYSIS OF 13 PATIENTS
    Hundsberger, T.
    Bruegge, D.
    Weder, P.
    Weber, J.
    Plasswilm, L.
    NEURO-ONCOLOGY, 2012, 14 : 88 - 88
  • [9] Salvage therapy with bevacizumab and chemotherapy (irinotecan or fotemustine) in recurrent high-grade gliomas
    Trevisan, E.
    Laguzzi, E.
    Picco, E.
    Ruda, R.
    Crasto, S. Greco
    Gaidolfi, E.
    Fabrini, M. G.
    Scotti, V.
    Caroli, M.
    Bazzoli, E.
    Guarneri, D.
    Soffietti, R.
    JOURNAL OF NEUROLOGY, 2009, 256 : S53 - S53
  • [10] TREATMENT OF CHILDREN WITH RECURRENT OR PROGRESSIVE HIGH-GRADE GLIOMAS WITH IRINOTECAN, TEMOZOLOMIDE, AND BEVACIZUMAB
    Parekh, Chintan
    Jubran, Rima
    Finlay, Jonathan
    Dhall, Girish
    NEURO-ONCOLOGY, 2008, 10 (05) : 834 - 834
12345